Open Access

Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib

  • Authors:
    • Panuwat Promsorn
    • Takashi Yamaguchi
    • Hisashi Kosaka
    • Kazunori Aoi
    • Katsunori Yoshida
    • Hideyuki Matsushima
    • Kosuke Matsui
    • Shinji Shimoda
    • Masaki Kaibori
    • Makoto Naganuma
  • View Affiliations

  • Published online on: July 10, 2024     https://doi.org/10.3892/mco.2024.2761
  • Article Number: 63
  • Copyright: © Promsorn et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Recently, the relationship between the relative dose intensity (RDI) and efficacy was demonstrated for lenvatinib therapy in patients with advanced hepatocellular carcinoma (HCC), with a higher RDI of lenvatinib monotherapy indicating a higher efficacy. However, not every patient can tolerate a high RDI during the course of treatment; therefore, add‑on combination therapy may be necessary for patients requiring a low RDI. The addition of transarterial chemoembolization (TACE) to lenvatinib therapy improves clinical outcomes. Therefore, the aim of the present study was to compare the clinical outcomes of lenvatinib plus TACE (the LEN‑TACE group) with those of lenvatinib alone (the LEN group) in patients with unresectable HCC with a high‑ or low‑RDI. A total of 66 patients with advanced HCC were enrolled in the present retrospective study. Eligible patients were those who initiated lenvatinib monotherapy between April 2018 and September 2020. Of these patients, 29 had an 8‑week RDI of ≥60%, 6 of which received LEN‑TACE. A further 37 patients had an 8‑week RDI of <60%, 7 of which received LEN‑TACE. In the high‑RDI group, both the radiological evaluations and the overall survival (OS) time were improved in those in the low‑RDI group. In addition, the median OS of patients treated with LEN‑TACE was longer compared with that of patients treated with lenvatinib alone in the low‑RDI group (P=0.0467). Therefore, the results of the present study revealed that early TACE should be considered instead of continuing lenvatinib only treatment in patients receiving an insufficient dose of lenvatinib, such as those with an 8‑week RDI of <60%.
View Figures
View References

Related Articles

Journal Cover

September-2024
Volume 21 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Promsorn P, Yamaguchi T, Kosaka H, Aoi K, Yoshida K, Matsushima H, Matsui K, Shimoda S, Kaibori M, Naganuma M, Naganuma M, et al: Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib. Mol Clin Oncol 21: 63, 2024.
APA
Promsorn, P., Yamaguchi, T., Kosaka, H., Aoi, K., Yoshida, K., Matsushima, H. ... Naganuma, M. (2024). Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib. Molecular and Clinical Oncology, 21, 63. https://doi.org/10.3892/mco.2024.2761
MLA
Promsorn, P., Yamaguchi, T., Kosaka, H., Aoi, K., Yoshida, K., Matsushima, H., Matsui, K., Shimoda, S., Kaibori, M., Naganuma, M."Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib". Molecular and Clinical Oncology 21.3 (2024): 63.
Chicago
Promsorn, P., Yamaguchi, T., Kosaka, H., Aoi, K., Yoshida, K., Matsushima, H., Matsui, K., Shimoda, S., Kaibori, M., Naganuma, M."Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib". Molecular and Clinical Oncology 21, no. 3 (2024): 63. https://doi.org/10.3892/mco.2024.2761